questionsmedicales.fr
Tumeurs
Tumeurs par siège
Tumeurs de l'abdomen
Tumeurs de l'abdomen : Questions médicales fréquentes
Termes MeSH sélectionnés :
Programmed Cell Death 1 Receptor
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs de l'abdomen : Questions médicales les plus fréquentes",
"headline": "Tumeurs de l'abdomen : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Tumeurs de l'abdomen : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-09",
"dateModified": "2025-04-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Tumeurs de l'abdomen"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Tumeurs par siège",
"url": "https://questionsmedicales.fr/mesh/D009371",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs par siège",
"code": {
"@type": "MedicalCode",
"code": "D009371",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.588"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Tumeurs du rétropéritoine",
"alternateName": "Retroperitoneal Neoplasms",
"url": "https://questionsmedicales.fr/mesh/D012186",
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs du rétropéritoine",
"code": {
"@type": "MedicalCode",
"code": "D012186",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.588.033.731"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nodule de Soeur Marie-Joseph",
"alternateName": "Sister Mary Joseph's Nodule",
"url": "https://questionsmedicales.fr/mesh/D058288",
"about": {
"@type": "MedicalCondition",
"name": "Nodule de Soeur Marie-Joseph",
"code": {
"@type": "MedicalCode",
"code": "D058288",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "C04.588.033.740"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Tumeurs de l'abdomen",
"alternateName": "Abdominal Neoplasms",
"code": {
"@type": "MedicalCode",
"code": "D000008",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Robert Stoehr",
"url": "https://questionsmedicales.fr/author/Robert%20Stoehr",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany."
}
},
{
"@type": "Person",
"name": "Abbas Agaimy",
"url": "https://questionsmedicales.fr/author/Abbas%20Agaimy",
"affiliation": {
"@type": "Organization",
"name": "Institute of Pathology, University Hospital Erlangen (UKER), Friedrich-Alexander University Erlangen-Nürnberg (FAU), Erlangen, Germany. abbas.agaimy@uk-erlangen.de."
}
},
{
"@type": "Person",
"name": "Naseema Gangat",
"url": "https://questionsmedicales.fr/author/Naseema%20Gangat",
"affiliation": {
"@type": "Organization",
"name": "Mayo Clinic, Rochester, MN, USA."
}
},
{
"@type": "Person",
"name": "Paul H Sugarbaker",
"url": "https://questionsmedicales.fr/author/Paul%20H%20Sugarbaker",
"affiliation": {
"@type": "Organization",
"name": "Center for Gastrointestinal Malignancies, MedStar Washington Hospital Center, Washington, District of Columbia, USA."
}
},
{
"@type": "Person",
"name": "David Chang",
"url": "https://questionsmedicales.fr/author/David%20Chang",
"affiliation": {
"@type": "Organization",
"name": "Westat, Rockville, Maryland, USA."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Programmed cell death-1 blockade therapy in melanoma: Resistance mechanisms and combination strategies.",
"datePublished": "2023-01-24",
"url": "https://questionsmedicales.fr/article/36645031",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/exd.14750"
}
},
{
"@type": "ScholarlyArticle",
"name": "MicroRNAs Targeting Programmed Cell Death Protein 1 (PD-1) Promote Natural Killer Cell Exhaustion in Rheumatoid Arthritis.",
"datePublished": "2022-12-24",
"url": "https://questionsmedicales.fr/article/36640056",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18502/ijaai.v21i6.11524"
}
},
{
"@type": "ScholarlyArticle",
"name": "Differential expression of programmed death 1 (PD-1) on various immune cells and its role in human leprosy.",
"datePublished": "2023-04-21",
"url": "https://questionsmedicales.fr/article/37153623",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fimmu.2023.1138145"
}
},
{
"@type": "ScholarlyArticle",
"name": "A High Programmed Cell Death Protein 1 Hormone Receptor Score on Skin Biopsy is Associated with Sézary Syndrome Diagnosis: A Study of 91 Patients with Erythroderma.",
"datePublished": "2022-09-06",
"url": "https://questionsmedicales.fr/article/35758515",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.2340/actadv.v102.1062"
}
},
{
"@type": "ScholarlyArticle",
"name": "Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.",
"datePublished": "2022-11-25",
"url": "https://questionsmedicales.fr/article/36442821",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.actbio.2022.11.043"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Tumeurs",
"item": "https://questionsmedicales.fr/mesh/D009369"
},
{
"@type": "ListItem",
"position": 3,
"name": "Tumeurs par siège",
"item": "https://questionsmedicales.fr/mesh/D009371"
},
{
"@type": "ListItem",
"position": 4,
"name": "Tumeurs de l'abdomen",
"item": "https://questionsmedicales.fr/mesh/D000008"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Tumeurs de l'abdomen - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Tumeurs de l'abdomen",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-15",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Tumeurs de l'abdomen",
"description": "Comment diagnostiquer une tumeur abdominale ?\nQuels tests sanguins sont utiles ?\nQuels symptômes indiquent une tumeur abdominale ?\nQuelle imagerie est la plus précise ?\nQuand faire une échographie abdominale ?",
"url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Tumeurs de l'abdomen",
"description": "Quels sont les symptômes courants des tumeurs abdominales ?\nLa jaunisse est-elle un symptôme ?\nPeut-on avoir des symptômes sans tumeur visible ?\nLes tumeurs abdominales causent-elles des vomissements ?\nComment la fatigue est-elle liée aux tumeurs ?",
"url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Tumeurs de l'abdomen",
"description": "Peut-on prévenir les tumeurs abdominales ?\nLe tabagisme augmente-t-il le risque ?\nL'alcool est-il un facteur de risque ?\nLes infections peuvent-elles causer des tumeurs ?\nLe surpoids est-il un risque ?",
"url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Tumeurs de l'abdomen",
"description": "Quels sont les traitements des tumeurs abdominales ?\nQuand est la chirurgie nécessaire ?\nLa chimiothérapie est-elle efficace ?\nQuels effets secondaires des traitements ?\nLa radiothérapie est-elle utilisée ?",
"url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Tumeurs de l'abdomen",
"description": "Quelles complications peuvent survenir ?\nLes tumeurs peuvent-elles causer des douleurs chroniques ?\nComment les tumeurs affectent-elles la digestion ?\nLes tumeurs abdominales peuvent-elles causer des infections ?\nQuelles sont les conséquences d'une métastase ?",
"url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Tumeurs de l'abdomen",
"description": "Quels sont les principaux facteurs de risque ?\nLes antécédents médicaux influencent-ils le risque ?\nL'exposition à des produits chimiques est-elle un risque ?\nLe stress a-t-il un impact sur le risque ?\nLes maladies génétiques augmentent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D000008?mesh_terms=Programmed+Cell+Death+1+Receptor&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une tumeur abdominale ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic se fait par imagerie (IRM, scanner) et biopsie."
}
},
{
"@type": "Question",
"name": "Quels tests sanguins sont utiles ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les marqueurs tumoraux comme l'AFP et le CA 19-9 peuvent aider au diagnostic."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une tumeur abdominale ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Douleurs abdominales, perte de poids, nausées et changements d'appétit."
}
},
{
"@type": "Question",
"name": "Quelle imagerie est la plus précise ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'IRM est souvent plus précise pour visualiser les tissus mous."
}
},
{
"@type": "Question",
"name": "Quand faire une échographie abdominale ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'échographie est utile pour évaluer des masses abdominales suspectes."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes courants des tumeurs abdominales ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent douleurs, ballonnements, nausées et perte d'appétit."
}
},
{
"@type": "Question",
"name": "La jaunisse est-elle un symptôme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la jaunisse peut indiquer une tumeur au foie ou des voies biliaires."
}
},
{
"@type": "Question",
"name": "Peut-on avoir des symptômes sans tumeur visible ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des symptômes peuvent apparaître même sans tumeur détectable."
}
},
{
"@type": "Question",
"name": "Les tumeurs abdominales causent-elles des vomissements ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les vomissements peuvent survenir en raison de l'obstruction intestinale."
}
},
{
"@type": "Question",
"name": "Comment la fatigue est-elle liée aux tumeurs ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La fatigue peut résulter de la maladie, des traitements ou de l'anémie."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les tumeurs abdominales ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures comme une alimentation saine et l'exercice peuvent réduire le risque."
}
},
{
"@type": "Question",
"name": "Le tabagisme augmente-t-il le risque ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque pour plusieurs types de tumeurs abdominales."
}
},
{
"@type": "Question",
"name": "L'alcool est-il un facteur de risque ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une consommation excessive d'alcool peut augmenter le risque de tumeurs hépatiques."
}
},
{
"@type": "Question",
"name": "Les infections peuvent-elles causer des tumeurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines infections, comme l'hépatite B, peuvent augmenter le risque de cancer du foie."
}
},
{
"@type": "Question",
"name": "Le surpoids est-il un risque ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité est associée à un risque accru de plusieurs tumeurs abdominales."
}
},
{
"@type": "Question",
"name": "Quels sont les traitements des tumeurs abdominales ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent chirurgie, chimiothérapie et radiothérapie."
}
},
{
"@type": "Question",
"name": "Quand est la chirurgie nécessaire ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La chirurgie est souvent nécessaire pour retirer la tumeur et les tissus environnants."
}
},
{
"@type": "Question",
"name": "La chimiothérapie est-elle efficace ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle peut réduire la taille des tumeurs et prévenir les récidives."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires des traitements ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent nausées, fatigue, et perte de cheveux."
}
},
{
"@type": "Question",
"name": "La radiothérapie est-elle utilisée ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elle est utilisée pour traiter certaines tumeurs abdominales localisées."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la métastase, l'obstruction intestinale et l'hémorragie."
}
},
{
"@type": "Question",
"name": "Les tumeurs peuvent-elles causer des douleurs chroniques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tumeurs peuvent provoquer des douleurs chroniques en raison de leur taille ou de leur emplacement."
}
},
{
"@type": "Question",
"name": "Comment les tumeurs affectent-elles la digestion ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent provoquer des obstructions, entraînant des problèmes digestifs."
}
},
{
"@type": "Question",
"name": "Les tumeurs abdominales peuvent-elles causer des infections ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tumeurs peuvent affaiblir le système immunitaire, augmentant le risque d'infections."
}
},
{
"@type": "Question",
"name": "Quelles sont les conséquences d'une métastase ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les métastases peuvent affecter d'autres organes, compliquant le traitement et le pronostic."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le tabagisme, l'alcool et des antécédents familiaux."
}
},
{
"@type": "Question",
"name": "Les antécédents médicaux influencent-ils le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents de maladies comme la colite peuvent augmenter le risque."
}
},
{
"@type": "Question",
"name": "L'exposition à des produits chimiques est-elle un risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains produits chimiques peut augmenter le risque de cancer abdominal."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut influencer la santé globale, mais son lien direct est moins clair."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques comme le syndrome de Lynch augmentent le risque."
}
}
]
}
]
}
Melanoma is a highly aggressive tumor derived from melanocytes. In recent years, the incidence and mortality of melanoma have gradually increased, seriously threatening human health. Classic treatment...
Natural killer (NK) cells play a role in the pathogenesis of rheumatoid arthritis (RA). Upregulated levels of programmed cell death protein 1 (PD-1) is a sign of exhausted NK cells that could be regul...
Leprosy is a chronic bacterial disease caused by...
Erythroderma is challenging to diagnose. The aim of this single-centre retrospective study was to identify factors that can be used to improve the diagnosis of erythroderma. Among 91 patients with ery...
Immune checkpoint blockade therapy targeting programmed death-1 (PD-1) or its major ligand programmed death-ligand 1 (PD-L1) has achieved remarkable success in the treatment of several tumors, includi...
The immune system uses various immune checkpoint axes to adjust responses, support homeostasis, and deter self-reactivity and autoimmunity. Nevertheless, non-small-cell lung carcinoma (NSCLC) can use ...
Pembrolizumab or nivolumab plus chemotherapy was approved as a first-line treatment for high programmed cell death ligand 1 (PD-L1)-expressing esophageal squamous cell carcinoma (ESCC) by the European...
Post hoc analysis of the Chinese JUPITER-06 study focusing on efficacy stratified by PD-L1 tumor proportion score (TPS; using JS311 antibody) was conducted. Electronic databases were searched to ident...
The post hoc analysis of JUPITER-06 showed more prominent clinical benefit with PD-1 antibody plus chemotherapy than with chemotherapy alone in both the high and low PD-L1-expressing subgroups. Five r...
This study provided novel evidence supporting the superiority of PD-1 antibody plus chemotherapy to chemotherapy alone in patients with advanced ESCC with low PD-L1 expression. Further studies of pred...
Major depression (MD) may be associated with inflammation and immunity. PD-1 (programmed death-1), PD-L1 (programmed death-ligand 1) and PD-L2 (programmed death-ligand 2) are among the inhibitory immu...
During a period of 2 years, patients with MD and healthy controls were recruited from a medical centre in this study. The diagnosis of MD was established according to the DSM-5 criteria. The severity ...
A total of 54 patients with MD and 38 healthy controls were recruited. According to the analyses, there is a significantly higher PD-L2 level in MD than in healthy controls and lower PD-1 level after ...
It was found that PD-1 pathway might play an important role in MD. We need a large sample to prove these results in the future....
Tumor-infiltrating lymphocytes are detectable in up to 75% of triple-negative breast cancer. The composition of these infiltrates may influence prognosis and is not known regarding regulatory or effec...
This was a retrospective observational study. Clinical and pathological data from 38 triple-negative breast cancer patients treated with neoadjuvant chemotherapy at the University Hospital (HUCFF/UFRJ...
Statistically significant changes in stromal tumor-infiltrating lymphocyte categories were observed before and post-neoadjuvant chemotherapy, with 32% of intermediate cases becoming high. The correlat...
In this study, we observed that chemotherapy significantly increases stromal tumor-infiltrating lymphocytes, CD8 T cells, as well as CD8/FoxP3 ratio. Most importantly, programmed cell death protein 1 ...
Melanoma is widely treated with programmed cell death-1 (PD-1) inhibitors. As part of their anti-tumor immunity effect, they increase the susceptibility to cutaneous immune-related adverse events (cIR...